Assessment of rate of major complications in transarterial chemoembolization using degradable starch microspheres versus permanent embolization particles in patients with hepatocellular carcinoma

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

STRAKA Matej ROHAN Tomáš MATKULČÍK Peter HUSTÝ Jakub ANDRAŠINA Tomáš

Year of publication 2022
Type Appeared in Conference without Proceedings
MU Faculty or unit

Faculty of Medicine

Citation
Description Purpose: To analyze whether transarterial chemoembolization (TACE) using degradable starch microspheres (DSM-TACE) or permanent embolizing particles (DEB-TACE) cause significant difference in rate of major periprocedural complications in patients with hepatocellular carcinoma (HCC). Materials and methods: Prospective assessment of major periprocedural complications in 226 TACE procedures between 2018-2021 in 57 consecutive patients with HCC was performed. Study group consists of 110 DSM-TACE procedures, the control group consists of 116 procedures using permanent embolizing particles. Major complications were followed up to 30 days after each TACE (contrast-enhanced CT, laboratory parameters, clinical status). Our data underwent statical analyses (chi-squared test). Results: There was significant difference in complication per procedure in the study and the control group (3% vs 14% p=0,006). Complications after TACE included severe postembolization syndrome (n=11), liver ischemia caused by reflux of permanent particles (n=4), liver abscess (n=2), cholangitis (n=2), allergic reaction (n=1). Conclusion: Patients with HCC treated with TACE using permanent embolization particles have significantly higher frequency of major postprocedural complication compared to patients with HCC treated with TACE using degradable particles.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.